Differences in gene expression between myxoid liposarcoma and Ewing sarcoma cell lines
FET fusion oncoproteins, containing the N-terminal of a FET protein (FUS, EWSR1 and TAF15) together with a DNA-binding transcription factor partner, are characteristic for around 20 different sarcomas and leukemias, including myxoid liposarcoma (MLS) and Ewing sarcoma (EWS). Many of these tumors have few other genetic abberrations. Using RNA-sequencing on MLS and EWS cell lines, we showed that gene expression patterns varied between FET sarcoma subtypes. Together with other data, the information from this experiment can help to determine the oncogenic mechanism in FET sarcomas and how a common oncogenic mechanism can give rise to different tumor types, explaining the tumor-type specificity of FET oncoproteins. Overall design: RNA sequencing of two Ewing sarcoma cell lines (EWS 6647 and TC-71) and three myxoid liposarcoma cell lines (MLS 1765-92, 402-91 and 2645-94), each in four replicates.